Neuland Labs. (NEULANDLAB)
STALWARTFairStock Score: 33/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹14,977 |
| Market Cap | ₹16,454.33 Cr |
| P/E Ratio | 91.86 |
| ROCE | 18.66% |
| ROE | 11.75% |
| Dividend Yield | 0.09% |
| Profit Growth | -40.26% |
| Debt/Equity | 0.16 |
| Sales Growth | 2.71% |
| Free Cash Flow | ₹1,900 Cr |
| Promoter Holding | 32.63% |
| 52-Week Range | ₹11,500 — ₹19,747 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹1,188.48 |
Neuland Labs. trades with a P/E ratio of 91.86, ROCE of 18.66%, ROE of 11.75%, profit growth of -40.26%, debt-to-equity of 0.16. The FairStock Score of 33/100 flags concerns across multiple fundamental dimensions that investors should examine carefully.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer